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Introduction
Patients with myelodysplastic syndromes (MDS) with a
deletion of 5q [del(5q)] defined by the International
Prognostic Scoring System1 (IPSS) as low- or intermediate-1-
risk (lower-risk) are considered to have a favorable prognosis
compared with that of patients with other types of MDS.2,3
However, it is now recognized that overall survival and pro-
gression to acute myeloid leukemia (AML) vary greatly
among patients with lower-risk del(5q) MDS. In a recent
study of 381 untreated patients with lower-risk del(5q) MDS,
the 2-year and 5-year overall survival rates were 86% and
61%, respectively, and the cumulative risks of AML were
4.7% and 14.7%, respectively.4 Transfusion dependency and
a bone marrow (BM) blast count of >5% at diagnosis were
significantly associated with increased risk of AML.
Interestingly, neither IPSS subgroup (low- or intermediate-1-
risk) nor the presence of one additional chromosomal abnor-
mality within the intermediate-1-risk subgroup had an impact
on outcome. In the MDS-004 phase III clinical trial (clinicaltri-
als.gov identifier: NCT00179621), which included 205 red
blood cell transfusion-dependent patients with IPSS-defined
low- or intermediate-1-risk del(5q) MDS, the 3-year overall
survival and AML-risk rates were 56% and 25%,
respectively.5 Failure to achieve treatment response was asso-
ciated with adverse outcomes, in line with previous reports.6
These studies indicate that the prognosis of patients with
lower-risk del(5q) MDS is less favorable than previously con-
sidered, and that factors other than IPSS classification have an
impact on patients’ outcomes.7-9
Molecular mutations, including TP53mutations, are emerg-
ing as independent prognostic factors.8 Using deep-sequenc-
ing technology, 18% of patients with lower-risk del(5q) MDS
were found to have TP53 mutated subclones which rendered
them at higher risk of progression.10 The negative prognostic
impact of TP53 mutations has been found in several other
studies, especially in high-risk and therapy-related MDS.8,11-21
Strong nuclear staining of the p53 protein by immunohisto-
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Del(5q) myelodysplastic syndromes defined by the International Prognostic Scoring System as low- or intermedi-
ate-1-risk (lower-risk) are considered to have an indolent course; however, recent data have identified a subgroup
of these patients with more aggressive disease and poorer outcomes. Using deep sequencing technology, we pre-
viously demonstrated that 18% of patients with lower-risk del(5q) myelodysplastic syndromes carry TP53mutat-
ed subclones rendering them at higher risk of progression. In this study, bone marrow biopsies from 85 patients
treated with lenalidomide in the MDS-004 clinical trial were retrospectively assessed for p53 expression by
immunohistochemistry in association with outcome. Strong p53 expression in ≥1% of bone marrow progenitor
cells, observed in 35% (30 of 85) of patients, was significantly associated with higher acute myeloid leukemia risk
(P=0.0006), shorter overall survival (P=0.0175), and a lower cytogenetic response rate (P=0.009), but not with
achievement or duration of 26-week transfusion independence response. In a multivariate analysis, p53-positive
immunohistochemistry was the strongest independent predictor of transformation to acute myeloid leukemia
(P=0.0035). Pyrosequencing analysis of laser-microdissected cells with strong p53 expression confirmed the TP53
mutation, whereas cells with moderate expression predominantly had wild-type p53. This study validates p53
immunohistochemistry as a strong and clinically useful predictive tool in patients with lower-risk del(5q)
myelodysplastic syndromes. This study was based on data from the MDS 004 trial (clinicaltrials.gov identifier:
NCT00179621).
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chemistry (IHC) has been used as a surrogate marker for
TP53 gene mutations in hematologic and other malignan-
cies, including large B-cell lymphoma.22-24 Recently, it was
demonstrated that p53 nuclear expression correlated with
hemizygous TP53 mutation and outcomes in relapsed
myeloma patients treated with lenalidomide.25
AML following MDS has a dismal prognosis, which
makes prediction essential, especially in patients who
potentially could be cured by stem cell transplantation. In
order to develop a clinically useful prognostic tool, we
measured p53 protein expression by IHC in a cohort of 85
patients with lower-risk del(5q) MDS from the MDS-004
clinical trial, and compared outcomes and responses to
lenalidomide treatment in patients with respect to strong
nuclear p53 expression. We demonstrate the independent
prognostic value of p53 IHC in this population of patients,
and show that strong nuclear staining reflects underlying
TP53 mutations. Our findings underscore the importance
of including molecular markers such as TP53mutations in
risk-assessment for del(5q) MDS patients.
Methods
Patients 
Formalin-fixed paraffin-embedded BM trephines from patients
enrolled in the phase III, randomized, double-blind, placebo-con-
trolled MDS-004 trial were retrieved.5 The MDS-004 trial assessed
the efficacy and safety of lenalidomide in 205 red blood cell trans-
fusion-dependent patients with low- or intermediate-1-risk del(5q)
MDS. The inclusion criteria and treatment schedule were as pre-
viously described;5 a bone marrow biopsy was recommended, but
not mandatory. The present study was conducted under the ethi-
cal consent for the MDS-004 trial. The original ethical permit did
not include any type of sequencing; therefore, TP53 deep-sequenc-
ing analysis was only possible in a subset of patients who were
still alive and provided consent to an ethical permit obtained after
the MDS-004 trial had been completed. In Sweden, gene-sequenc-
ing analysis was performed under a separate national ethical per-
mit, which was used for the pyrosequencing of laser-microdissect-
ed BM cells.
Bone marrow morphology and immunohistochemistry
Overall, 131 BM trephines from 85 of the 205 patients (41%;
IHC study cohort) obtained at baseline and follow-up were
assessed in a blinded fashion. Serial BM biopsies were available for
25% (21 of 85) of the patients. BM cellularity and fibrosis were
assessed according to European consensus guidelines.26
The percentage and intensity of p53 staining was assessed
based on a total manual count of 1000 BM hematopoietic cells
(lymphocytes/lymphoid aggregates excluded) and graded as: 0
(negative); 1+ (weakly positive); 2+ (moderately positive); and 3+
(strongly positive). The entire BM trephine was also assessed using
a Modified Quick Score;27 a score of ≥3 was used to define p53-
positive staining as previously described.28 In addition, all samples
were assessed blindly for the percentage of p53-DO1 strongly pos-
itive (3+) cells by three hematopathologists from institutions in
different countries. A computerized imaging system was used to
measure p53 and grade it as in the manual counting. BM biopsies
from 50 patients with secondary cytopenias were included as neg-
ative controls for internal validation of the p53 staining.
TP53 mutation analysis 
Deep-sequencing mutation analysis was performed in nine of
85 (11%) patients using DNA from the formalin-fixed paraffin-
embedded baseline biopsy and, if available, a follow-up sample. In
three patients with known TP53 mutations, laser-microdissection
of p53-immunolabeled cells was performed to study the relation-
ship between protein expression and TP53 mutation. Cells with
strong (3+), moderate (2+), and negative p53-staining were
microdissected and collected separately (>1000 nucleated
cells/tube) for DNA extraction (Arcturus®PicoPure® DNA
Extraction Kit; Applied Biosystems, Carlsbad, CA, USA).
Oligonucleotides and pyrosequencing information are presented
in Online Supplementary Table S1.
Statistical analysis
Demographic and baseline characteristics of the IHC cohort
(n=85) and patients in the MDS-004 trial without IHC data
(n=120) were compared using the two-sided t-test for continu-
ous variables and Fisher exact test for categorical variables. The
Fisher exact test and the Kaplan-Meier methods were used to
compare response rates and time-to-event endpoints. A compet-
ing risk approach was used to analyze time to progression with-
out AML. Cox proportional hazard modeling was used to eval-
uate multiple risk factors for AML progression and overall sur-
vival. The final model only included risk factors with a P-value
of <0.1, applying the backward elimination variable selection
method.
Results
Patients
Patients in the MDS-004 trial (n=205) were randomized
to lenalidomide 5 mg (n=69) or 10 mg (n=69), or placebo
(n=67); the corresponding figures for the IHC cohort
(n=85) were 27, 33, and 25 patients, respectively (Online
Supplementary Table S2). Of the 25 patients randomized to
placebo in the IHC cohort, 22 crossed-over to active treat-
ment after 16 weeks; the remaining three patients discon-
tinued placebo treatment at days 18, 26, and 30, but were
followed for AML progression and survival. Baseline
demographics, clinical data, IPSS risk groups, and World
Health Organization subgroups did not differ between the
IHC cohort and the MDS-004 trial patients without BM
trephine biopsies (Online Supplementary Table S3).
Moreover, outcomes in terms of therapeutic response, sur-
vival, and AML transformation were similar between the
two groups.
Reproducibility of the p53 immunohistochemistry
staining
Results for the manual versus automated measurements
were highly concordant with respect to the frequency of
cells with weak (1+), moderate (2+), and strong (3+) p53-
staining for both p53 monoclonal antibodies (Pearson cor-
relation coefficient r=0.9593, r2=0.9203; P<0.01) (Online
Supplementary Figure S1). In addition, the manual counts
for the p53-DO1 and p53-DO7 antibodies were highly
associated for different staining intensities (Pearson corre-
lation coefficient r=0.9601, r2=0.9218; P<0.01); therefore,
all subsequent statistical analyses were based on data from
the manual assessment of the p53-DO1 antibody only. In
addition, all BM samples were assessed by three inde-
pendent investigators to evaluate inter-observer agree-
ment with regard to the presence of cells with strong p53
expression when using the 1% threshold. Cohen’s kappa
test was applied and indicated perfect agreement between
the three investigators (data not shown).
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Strong p53 protein expression in a subset of bone 
marrow samples
A total of 30 of 85 patients (35%) had ≥1% BM progen-
itor cells with strong (3+) p53-DO1 expression in the ini-
tial screening sample: ≥1% to <2% in 14 patients; 2% to
<5% in 11 patients; and ≥5% in five patients. Figure 1
shows an example of p53 staining. 
Detailed clinical and morphological data for the IHC
study cohort are presented in Online Supplementary Table
S2. All samples with ≥1% strong p53-staining by IHC
were subsequently double-stained for CD34, hemoglobin,
glycophorin A, and myeloperoxidase. p53 was predomi-
nantly expressed in erythroid progenitor cells, but also in
the granulopoietic cell lineage and in rare cases in
megakaryocytes; the latter was only seen in patients with
refractory anemia with excess blasts-1. None of the sam-
ples with secondary, non-MDS related cytopenia showed
strong p53 staining.
Strong p53 expression reflects the TP53 gene mutation
TP53 sequencing analysis was performed in a subset of
nine (11%) patients in the IHC study cohort from whom
additional consent was obtained (Online Supplementary
Table S4). Mutations were detected in three patients:
C275F and E294K missense mutations were associated
with strong p53 expression, whereas the K291* nonsense
mutation was negative by IHC. In one patient (patient 37)
the mutation was acquired at a later time point which was
reflected by positive IHC, whereas previous samples
stained negative. In the remaining six patients without
TP53 mutations, IHC was negative in four, whereas two
patients had 1.2% and 1.6% BM progenitor cells with
strong p53 expression. However, it should be noted that
the material used for sequencing was whole BM sections
which made this method less sensitive than previous stud-
ies using archived BM smears.10 In seven patients, P72R
polymorphisms were identified. These are known TP53
polymorphisms that do not represent gene mutations and
were negative by IHC, as expected. 
Single-cell laser-microdissection was performed in serial
BM samples from three patients to assess the relationship
between the degree of p53 protein expression and muta-
tion. Of these, patient 34 was also part of the IHC cohort
(Figure 2). The mutational allelic burden in microdissected
cells with strong (3+) p53-staining was around 45%, indi-
cating that 90% of the cells carried the mutation. In con-
trast, cells from the same sample with moderate (2+) p53-
staining predominantly had wild-type TP53 (allelic burden
around 16%). Online Supplementary Figure S2A-C shows
serial data from these three patients, including the correla-
tion between the percentage of strong (3+) p53-staining
cells and the allelic burden by pyrosequencing analysis.
Online Supplementary Figure S2D shows data for patient 37,
obtained by deep-sequencing using DNA from whole BM
sections.
Strong p53 expression predicts shorter overall survival
and higher risk of developing acute myeloid leukemia
The impact of strong p53-staining on outcome was sepa-
rately assessed for the presence of any strong p53-staining
cells versus none, for ≥1% and ≥2% cutoffs, and for the
whole IHC cohort by <1% (n=55), ≥1% to <2% (n=14),
and ≥2% (n=16). As the ≥1% to <2% and ≥2% curves for
both overall survival and progression to AML were similar-
ly associated with worse outcome (overlapping) and well
separated from the <1% curve (Online Supplementary Figures
S3 and S4), the 1% cutoff was used for all subsequent
analyses, with ≥1% defined as “p53-positive” and <1% as
“p53-negative”. Baseline demographics, clinical data, and
World Health Organization subgroups did not differ signif-
icantly between patients with ≥1% (n=30) and <1% (n=55)
strong p53-staining (Online Supplementary Table S5).
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Figure 1. The p53-DO1 stain
shows cells with moderate (2+)
and strong (3+) nuclear staining
(top). The lower left panel shows
a BM sample with only scattered
strong p53-positive staining (red
circle) around the 1% level by
both manual and automated
image assessment. The lower
right panel shows a BM sample
with the presence of scattered
weak (1+; yellow circle) and mod-
erate (2+; orange circle) p53-pos-
itive staining cells, but no cells
with strong (3+) nuclear staining. 
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The median overall survival was 2.4 years (interquartile
range [IQR] 1.7-3.7) and 4.3 years (IQR 3.5-6.4) in p53-
positive and p53-negative patients, respectively
(P=0.0175) (Figure 3). The 5 year rates to AML progression
were 56.3% (IQR 33.3-79.3) and 19.6% (IQR 7.1-32.2),
respectively (P=0.0006) (Figure 4). The 5-year rates to
AML progression using death without AML as a compet-
ing risk were 41.3% (IQR 23.0-58.8) and 14.5% (IQR 6.7-
25.2), respectively (P=0.0021). Similarly, p53 IHC positivi-
ty was significantly associated with worse outcomes
(overall survival and AML risk) in patients randomized to
lenalidomide (n=60); 21 of 60 patients (35%) who received
lenalidomide had ≥1% strong p53-staining cells compared
with nine of 25 patients (36%) who received placebo
(Online Supplementary Table S2). For patients randomized
to lenalidomide (n=60), the median overall survival was
2.0 years (range, 1.2-5.0) and 4.1 years (range, 2.9-5.7) in
p53-positive and p53-negative patients, respectively
(P=0.0830). The 5-year rates to AML progression were
51.3% (IQR 25.2-77.4) and 20.8% (IQR 5.3-36.3) for p53-
positive and p53-negative patients, respectively
(P=0.0047); the 5-year rates to AML progression using
death without AML as a competing risk were 39.8% (IQR
18.3-60.8) and 15.4% (IQR 6.1-28.6), respectively
L. Saft et al.
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Figure 2. Laser-microdissection
of BM cells with strong (3+; red
circle), moderate (2+; orange
circle), and negative p53-stain-
ing collected in three separate
tubes from the same formalin
fixed, paraffin-embedded BM
sample (patient 34, BM sample
at 105 months from initial diag-
nosis). TP53 mutation analysis
by pyrosequencing using DNA
from microdissected cells. The
images were taken with a Leica
Laser Microscope at 60× mag-
nification before (left) and after
(right) laser-microdissection;
p53-negative microdissected
cells are not shown in the upper
images. Patient 34 had classi-
cal 5q− syndrome [46, XX,
del(5q)] with a previously
known C275F (G>T) TP53
mutation. 
Figure 3. Overall survival by
the presence of <1% (p53-
negative) and ≥1% (p53-posi-
tive) BM progenitor cells with
strong (3+) p53 staining.
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(P=0.0140) (data not shown). Moreover, p53 IHC positivity
was associated with adverse outcome in patients with iso-
lated del(5q) and <5% BM blast count (n=48) (data not
shown). The median survival after AML progression was
only 0.24 years (data not shown).
Similar results were obtained using the p53 IHC
Modified Quick Score to compare patients with a score of
≥3 versus <3 (data not shown). However, the P-values for the
Modified Quick Score (P=0.04 and P=0.006, respectively)
were higher than those for the 1% cutoff level and were
not used in the final recommendation.
Using Cox proportional hazard modeling a multivariate
analysis was performed to evaluate multiple risk factors
for overall survival and AML progression (Table 1). p53
≥1% versus <1% was the strongest predictor of progres-
sion to AML (P=0.0035), whereas p53 IHC and, interest-
ingly, male sex independently predicted for overall sur-
vival (both P<0.001).
Table 1. Multivariate and univariate Cox proportional regression models for AML progression and overall survival for the IHC study cohort.
Baseline characteristics AML progression Overall survival
Univariate model Multivariate final model Univariate model Multivariate final model
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age, years 0.997 (0.961-1.034) 0.8617 1.021 (0.998-1.045) 0.0782 1.021 0.0856
Sex (male vs. female) 0.335 (0.044-2.528) 0.2887 3.482 (1.910-6.347) <0.001 4.088 (2.135-7.827) <0.001
IPSS categories (high-, int-2-, ) 1.430 (0.503-4.059) 0.5021 0.785 (0.434-1.420) 0.4236
int-1-risk vs. low-risk
FAB classification 1.678 (0.478-5.897) 0.4195 1.813 (0.839-3.921) 0.1304
(RAEB, CMML vs. RA, RARS)
Duration of MDS, years 1.028 (0.944-1.120) 0.5200 0.967 (0.895-1.046) 0.4047
Transfusion burden, units/8 weeks 1.189 (1.021-1.385) 0.0259 1.149 (0.985-1.341) 0.0781 1.120 (1.014-1.238) 0.0254
26-week transfusion independence 0.591 (0.239-1.463) 0.2554 0.406 (0.222-0.742) 0.0034 0.444 (0.241-0.819) 0.0093
Bone marrow blast group 2.326 (0.660-8.192) 0.1889 2.198 (0.973-4.967) 0.0582
(<5% vs. ≥5%)
N. of cytopenia(s) (2 or 3 vs. 1) 1.622 (0.700-3.760) 0.2593 0.806 (0.463-1.404) 0.4465
Platelet count, ×109/L 1.000 (0.997-1.003) 0.7500 0.998 (0.996-1.000) 0.1191 0.998 (0.997-1.000) 0.0451
Absolute neutrophil count, ×109/L 0.942 (0.773-1.149) 0.5562 1.020 (0.945-1.101) 0.6150
Hemoglobin, g/dL 0.815 (0.530-1.253) 0.3507 0.896 (0.687-1.167) 0.4139
Erythropoietin level, mIU/mL 1.008 (0.999-1.018) 0.0763 1.007 (1.001-1.013) 0.0247
Ferritin level, mol/L 1.000 (1.000-1.000) 0.1612 1.000 (1.000-1.000) 0.1578
del(5q) (complex vs. isolated) 0.735 (0.287-1.878) 0.5195 1.046 (0.608-1.798) 0.8713
WPSS group (very high, high vs. 1.010 (0.384-2.654) 0.9846 1.469 (0.818-2.639) 0.1976
intermediate, very low/low)
p53 IHC (≥1% vs. <1%) 4.017 (1.707-9.453) 0.0014 3.618 (1.525-8.583) 0.0035 1.869 (1.107-3.157) 0.0193 2.887 (1.608-5.185) <0.001
AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; FAB: French-American-British; HR: hazard ratio; IHC: immunohistochemistry; Int: intermediate; IPSS: International Prognostic
Scoring System; MDS: myelodysplastic syndromes; RA: refractory anemia; RAEB: RA with excess blasts; RARS: RA with ring sideroblasts; WPSS: World Health Organization-based Prognostic Scoring
System; Statistically significant results are shown in bold.
Figure 4. Probability of AML progres-
sion by the presence of <1% (p53-
negative) and ≥1% (p53-positive) BM
progenitor cells with strong (3+) p53
staining.
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Strong p53-expression is associated with reduced cyto-
genetic response, but not transfusion independence 
There was no difference in red blood cell-transfusion
independence (RBC-TI) between p53-positive and p53-
negative patients in the total cohort or in those patients
randomized to receive lenalidomide. In the total cohort
(n=85), ≥26 week RBC-TI was achieved by 30.0% (9 of 30)
of p53-positive and 36.4% (20 of 55) of p53-negative
patients (P=0.636) (Online Supplementary Table S6).
Similarly, for patients randomized to receive lenalidomide
10 mg (n=33), RBC-TI response was achieved in 62.5% (5
of 8) and 52.0% (13 of 25) of p53-positive and p53-nega-
tive patients, respectively (P=0.699). In contrast, p53 IHC
status was significantly associated with cytogenetic
response (complete and partial response taken together):
51% (18 of 35) of p53-negative patients versus 14% (3 of
21) of p53-positive patients had a cytogenetic response
(P=0.009). As cytogenetic response rates differed for
patients receiving lenalidomide 5 mg or 10 mg in the
MDS-004 trial, cytogenetic response rates were also
specifically evaluated for each lenalidomide dose level in
the present study. For patients randomized to lenalido-
mide 10 mg, one of eight (12.5%) p53-positive patients
had a cytogenetic response compared to 16 of 19 (84.2%)
p53-negative patients.
Therapeutic response by 26-week RBC-TI in combina-
tion with a p53-negative IHC status was associated with
excellent outcome, and the median overall survival for this
group was not reached at the end of the MDS-004 study
period (data not shown). By comparison, the median overall
survival was 2.3 years (IQR 1.4-3.7) and 3.9 years (IQR 2.3-
4.9) for non-responding p53-positive and p53-negative
patients, respectively. The 5-year cumulative incidences of
AML were 71.1% (IQR 43.4-100) and 24.3% (IQR 4.5-
44.2), respectively. For responding patients, the 5-year rates
of AML progression were 30.0% (IQR 0.0-65.7) and 15.6%
(IQR 0.0-31.8) in p53-positive and p53-negative patients,
respectively. The association was also significant when
using death without AML as a competing risk (P=0.0125).
Although p53 IHC status showed no association with the
duration of RBC-TI (P=0.44), the curves separated after 18
months with the response duration being shorter in the
p53-positive patients (Online Supplementary Figure S5).
Increase in p53 protein expression predicts disease
progression and cytogenetic evolution
The value of p53 IHC staining during follow-up was
assessed in serial BM samples from 21 patients (25%)
L. Saft et al.
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Figure 5. Increase of p53 in eight of 21 patients after 3 months, and in one patient (patient 5) after 12 months. Patients 5, 6, 9, and 17 had
cytogenetic evolution with complex karyotypes at 12, 22, 6, and 3 months, respectively. The decrease in p53 in the last sample in patient 8
may reflect very low BM cellularity (10%). The histology panels show p53-DO1 staining in BM samples from Patient 5 at screening (upper right)
and after 12 months (lower left) at 20×/40× magnification. Cells with strong (3+) p53 expression were negative for CD34 (lower middle) and
positive for hemoglobin (lower right). No increase in CD34+ cells was seen, but aberrant expression of CD34 in megakaryocytes was noted. 
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(Online Supplementary Table S7). At the scheduled 12-week
assessment, an increase in p53 expression from baseline
was seen in eight patients (Figure 5); 12 patients remained
negative and one patient had inadequate BM samples at 3
and 6 months, but adequate material at 12 months. The
increase in p53-staining was associated with cytogenetic
evolution (all complex karyotypes) in four patients
(patients 5, 6, 9, and 17; all randomized to lenalidomide 10
mg). Overall, six of the eight p53-positive patients devel-
oped AML within 13-44 months, compared with two of
12 patients who were p53-negative (P<0.01). The increase
in p53 by IHC at 12 weeks was also associated with short-
er overall survival compared with that of patients who
remained p53-negative (P=0.0005).
In addition, we assessed p53 IHC status and TP53muta-
tional status in serial BM samples from four patients,
including single-cell laser-microdissection in three
patients’ samples, as described previously (Online
Supplementary Figure S2). Briefly, two patients (Online
Supplementary Figure S2A,B) had small TP53 mutated sub-
clones already at initial diagnosis which, at first, remained
stable, but then increased as the patients’ disorder pro-
gressed to high-risk MDS. The TP53mutation was reflect-
ed by the presence of BM progenitors with strong p53-
staining at the corresponding time points. The remaining
two patients (Online Supplementary Figure S2C,D) acquired
TP53 mutations at 52 and 75 months, associated with an
increase in p53 by IHC. The acquisition of TP53mutations
was associated with rapid disease progression.
Discussion
This study demonstrates the utility of p53 IHC as a sig-
nificant and independent clinical decision-making tool in
lower-risk del(5q) MDS patients treated with lenalido-
mide. Strong p53 expression of ≥1% prevalence was inde-
pendently associated with a higher risk of AML transfor-
mation and poor overall survival. The results for manual
versus automated p53 counting were highly concordant
and the assessment of strong p53-staining by three inde-
pendent hematopathologists reflected high inter-observer
reproducibility. p53 IHC status was not associated with
the achievement or duration of RBC-TI but did influence
overall survival, while in the original report of the MDS-
004 study, RBC-TI >8 weeks was associated with better
overall survival.5 Interestingly, p53 IHC status was associ-
ated with achievement of a cytogenetic response to
lenalidomide. Complete hematologic response without
disappearance of del(5q) is, therefore, insufficient to recog-
nize patients with a low risk of progression, when consid-
ering p53 status at baseline. The dismal survival after AML
transformation underscores the importance of predicting
rather than treating this condition. 
A strong association between p53 protein expression,
TP53mutation, and adverse outcome has been reported in
various hematologic malignancies including MDS.18,23-25,29-34
TP53mutations occur primarily in high-risk/therapy-relat-
ed MDS, MDS-derived leukemia, and in the context of
complex chromosomal abnormalities including
del(17p).11,12,14,15,18-20,35,36 Studies also reported on the poor
prognostic impact of TP53 mutations and the association
between TP53 mutations and poor therapy response.
Interestingly, a high-frequency of chromosome 5 abnor-
malities was found in patients with TP53mutations.16,35,37,38
In fact, a recent study encompassing 318 MDS patients of
all IPSS categories found that TP53mutations were strong-
ly correlated with aberrations of chromosome 5.28 The
TP53mutant clones persisted in patients not responding to
chemotherapy. Our present findings underscore the role of
the TP53 pathway in the pathogenesis of lower-risk
del(5q) MDS as well. 
Our previous study,10 as well as two recent investiga-
tions using conventional Sanger sequencing in patients
with lower-risk del(5q) MDS,39 and higher-risk MDS and
AML,7 found that patients with TP53 mutations do not
obtain a complete cytogenetic response to lenalidomide.
Although the 1% cutoff level put forward in this study
is arbitrary, it is able to divide patients into two groups
with very different outcomes. Of the 55 patients with
<1% strong p53-staining cells, 40 patients had none and
15 patients had 0.2-0.9% cells. We do not know how
many TP53 mutated cells are needed to promote disease
progression in an individual patient. Nevertheless, the out-
come curves for patients with ≥1% p53-positive cells were
identical to those using the 2% cutoff, and significantly
different from those with <1% p53-positive cells. In fact,
p53-positive IHC ≥1% was the strongest independent pre-
dictor of AML transformation and also an independent
predictor of overall survival. Thus, even the presence of
small p53-positive populations has prognostic signifi-
cance. Recently, a similar effect was observed for NRAS
mutations in patients with lower-risk MDS.40
In our previous study,10 nine of ten patients with a muta-
tion showed >2% strong p53-staining cells. Interestingly,
the association with disease progression and AML risk
was stronger for IHC compared with TP53 mutation, an
observation also made in cases of pediatric glioma.41
Failure to detect TP53 mutations in IHC-positive sam-
ples may reflect the presence of very small subclones and
dilution of hematopoietic DNA. In contrast to our previ-
ous study which used DNA from BM smears or
biobanked samples,10 deep-sequencing in the present
study was performed on DNA from sections of biopsies,
including varying amounts of hematopoietic and non-
hematopoietic cells, and stromal components. The nega-
tive mutational analysis in two patients with 1-2% IHC-
positive cells is, therefore, in line with previous reports.
Also, by separately analyzing DNA from both bulk BM
cells and microdissected cells with strong p53-staining, we
demonstrated that a small fraction of cells with mutated
TP53 can exist without detection by bulk tissue sequenc-
ing (data not shown). This indicates greater sensitivity of the
p53 IHC method for identifying patients with small TP53
mutant clones. However, the small number of BM samples
that were assessed by IHC and sequencing is a limitation
in the present study and the correlation between IHC and
TP53 mutational status should be further assessed in a
larger cohort.
A drawback of the IHC method is that it fails to detect
nonsense mutations giving rise to a stop codon. However,
such mutations occur in <10% of high-risk myeloid malig-
nancies and seem to be uncommon in lower-risk del(5q)
MDS. None of the TP53 mutated patients with lower-risk
del(5q) MDS in the study by Kulasekararaj et al.28 or in our
previous report10 had stop codon mutations and, in the
present study, only one nonsense mutation was detected
by deep sequencing. Therefore, a negative IHC status, in
spite of an underlying mutation, is likely to be infrequent
in this population.
p53 protein expression predicts outcome in MDS
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Strong p53-expression has occasionally been described in
hematologic malignancies and non-neoplastic conditions in
the absence of a TP53 mutation, indicating alternative
mechanisms of acquiring a p53-positive phenotype.12,21,33,42-44
One of the major factors contributing to p53 stabilization is
via expression of p14ARF.45,46 Alternatively, inhibition of
MDM2-mediated degradation of p53 could block the
degradation of p53 protein.47,48 Studies by Barlow et al.49 and
Pellagatti et al.50 have elegantly shown that wild-type p53
activation is a key mechanism underlying the anemia of the
5q− syndrome, with moderate p53 IHC staining observed
in these studies. However, in our experience, strong p53-
staining is not seen in normal/reactive BM samples. Here,
we microdissected cells with strong and moderate staining,
and demonstrated an underlying mutation in the former,
but not in the latter. 
The study of sequential BM samples demonstrated that
an increase in p53-positive cells may predict disease pro-
gression and cytogenetic evolution. Repeated testing may,
therefore, be a way to investigate patients with borderline
p53 IHC frequencies. In addition, the development of non-
histological methods, including flow cytometry and
immunocytochemistry, to assess p53-protein expression
could be useful. 
In conclusion, we found that strong p53 protein expres-
sion by IHC is the strongest independent predictor of
AML transformation, and also an independent predictor of
overall survival and lower cytogenetic response in lower-
risk del(5q) MDS patients treated with lenalidomide.
Furthermore, the presence of BM progenitor cells with
strong nuclear p53 expression may reflect an underlying
TP53mutation. As deep-sequencing at present is neither a
validated nor a generally available method, we suggest
that assessment of p53 by IHC should be integrated in the
routine diagnostic work-up and follow-up of del(5q) MDS
patients. Moreover, TP53 mutational status should be
included in the risk assessment of del(5q) MDS patients.
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